DE69627307D1 - Verwendung einer rekombinanten dna für die herstellung eines medikaments, wobei die rekombinante dna eine dna umfasst, die die sm1-isoform des proteins der schweren kette von myosin der glatten muskulatur codiert - Google Patents

Verwendung einer rekombinanten dna für die herstellung eines medikaments, wobei die rekombinante dna eine dna umfasst, die die sm1-isoform des proteins der schweren kette von myosin der glatten muskulatur codiert

Info

Publication number
DE69627307D1
DE69627307D1 DE69627307T DE69627307T DE69627307D1 DE 69627307 D1 DE69627307 D1 DE 69627307D1 DE 69627307 T DE69627307 T DE 69627307T DE 69627307 T DE69627307 T DE 69627307T DE 69627307 D1 DE69627307 D1 DE 69627307D1
Authority
DE
Germany
Prior art keywords
recombinant dna
dna
heavy chain
smooth muscle
myosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69627307T
Other languages
English (en)
Other versions
DE69627307T2 (de
Inventor
Kazuhide Hasegawa
Emi Arakawa
Shoji Oda
Yuzuru Matsuda
Katsuhito Takahashi
Michihiro Sugahara
Haruo Ishiyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vessel Research Laboratory Co Ltd
Osaka Prefecture
Original Assignee
Vessel Research Laboratory Co Ltd
Osaka Prefecture
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vessel Research Laboratory Co Ltd, Osaka Prefecture filed Critical Vessel Research Laboratory Co Ltd
Application granted granted Critical
Publication of DE69627307D1 publication Critical patent/DE69627307D1/de
Publication of DE69627307T2 publication Critical patent/DE69627307T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69627307T 1995-01-25 1996-01-25 Verwendung einer rekombinanten dna für die herstellung eines medikaments, wobei die rekombinante dna eine dna umfasst, die die sm1-isoform des proteins der schweren kette von myosin der glatten muskulatur codiert Expired - Fee Related DE69627307T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP1008595 1995-01-25
JP1008595 1995-01-25
PCT/JP1996/000134 WO1996023069A1 (fr) 1995-01-25 1996-01-25 Adn de recombinaison prepare par integration d'adn qui code une proteine isoforme sm1 a chaine lourde de myosine dans un vecteur d'adn, et micro-organisme et remede contre l'arteriosclerose contenant tous deux ledit adn de recombinaison

Publications (2)

Publication Number Publication Date
DE69627307D1 true DE69627307D1 (de) 2003-05-15
DE69627307T2 DE69627307T2 (de) 2004-03-04

Family

ID=11740510

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69627307T Expired - Fee Related DE69627307T2 (de) 1995-01-25 1996-01-25 Verwendung einer rekombinanten dna für die herstellung eines medikaments, wobei die rekombinante dna eine dna umfasst, die die sm1-isoform des proteins der schweren kette von myosin der glatten muskulatur codiert

Country Status (13)

Country Link
US (1) US6593304B1 (de)
EP (1) EP0806477B1 (de)
JP (1) JP3092944B2 (de)
KR (1) KR19980701695A (de)
AT (1) ATE236977T1 (de)
AU (1) AU711757B2 (de)
CA (1) CA2211468A1 (de)
DE (1) DE69627307T2 (de)
FI (1) FI973104A (de)
HU (1) HUP9801762A1 (de)
NO (1) NO973421L (de)
NZ (1) NZ300270A (de)
WO (1) WO1996023069A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11285333A (ja) * 1998-02-05 1999-10-19 Vessel Research Laboratory:Kk 変異型平滑筋ミオシン重鎖遺伝子を有する非ヒト動物の胚幹細胞および非ヒト動物
CN1321672A (zh) * 2000-04-29 2001-11-14 上海博德基因开发有限公司 一种新的多肽——人肌球蛋白重链12－14和编码这种多肽的多核苷酸
US6974688B2 (en) 2001-08-10 2005-12-13 Cytokinetics, Inc. Human smooth muscle myosin heavy chain
US10590452B2 (en) 2017-12-20 2020-03-17 University Of Seoul Industry Cooperation Foundation DNA-Mn hybrid particles and method of manufacturing the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0646841A (ja) 1992-07-24 1994-02-22 Kyowa Hakko Kogyo Co Ltd トランスフェリン非要求性細胞

Also Published As

Publication number Publication date
FI973104A0 (fi) 1997-07-24
EP0806477B1 (de) 2003-04-09
HUP9801762A1 (hu) 1998-11-30
JP3092944B2 (ja) 2000-09-25
CA2211468A1 (en) 1996-08-01
AU711757B2 (en) 1999-10-21
KR19980701695A (ko) 1998-06-25
WO1996023069A1 (fr) 1996-08-01
US6593304B1 (en) 2003-07-15
NO973421L (no) 1997-09-22
NZ300270A (en) 1998-09-24
ATE236977T1 (de) 2003-04-15
AU4496196A (en) 1996-08-14
EP0806477A4 (de) 2000-01-05
EP0806477A1 (de) 1997-11-12
DE69627307T2 (de) 2004-03-04
NO973421D0 (no) 1997-07-24
FI973104A (fi) 1997-09-24

Similar Documents

Publication Publication Date Title
DE60023870T2 (de) Verfahren zur herstellung von 3-aryloxy-3-arylpropylamine und deren zwischenprodukte
ES2115896T3 (es) Composicion cosmetica que contiene como agente reductor un n-mercapto-alquil alcandiamida o una de sus sales cosmeticamente aceptable.
DE59303365D1 (de) Derivate in der vitamin d-reihe mit modifikationen in der 20 position, verfahren zu ihrer herstellung, zwischenprodukte für dieses verfahren, diese derivate enthaltende pharmazeutische präparate sowie deren verwendung zur herstellung von arzneimitteln
ATE315050T2 (de) Verfahren zur herstellung von mehrfach vernetzten hyaluronsäurederivaten
MX9606013A (es) Lacasas purificadas de myceliophthora y acidos nucleicos que codifican para las mismas.
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
SI0852585T1 (en) Method for treating alzheimer's disease using glial cell line-derived neurotrophic factor (gdnf) protein product
EP0701563A4 (de) Gen transfer zur behandlung von bindegewebe eines säugetierwirtes
DE3854950D1 (de) Vascular-antikoagulierende Proteine, DNA die diese kodieren, Verfahren zu deren Herstellung sowie deren Verwendung
BR9714493A (pt) Composição cosmética, processo de tratamento cosmético das fibras queratìnicas e utilização de uma composição.
NL300272I1 (nl) DNA dat humaan papillomavirus type 18 codeert.
DE69926254D1 (de) Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden
DK0386452T3 (da) Diphenylheteroalkylderivater, fremgangsmåde til fremstilling heraf og lægemidler og kosmetika indeholdende disse
ATE195346T1 (de) Rekombinante dna moleküle die aminopeptidase enzyme kodieren und ihre anwendung für die herstellung von impfstoffen gegen helminth infektionen
DE69635207D1 (de) Auf Chromosom 1 lokalisiertes Gen dessen Genprodukt mit der Alzheimerschen Krankheit assoziiert ist.
WO2004019893A3 (en) Modulators of angiogenesis
DE69627307D1 (de) Verwendung einer rekombinanten dna für die herstellung eines medikaments, wobei die rekombinante dna eine dna umfasst, die die sm1-isoform des proteins der schweren kette von myosin der glatten muskulatur codiert
ATE212360T1 (de) Polyethylenglycol-hirudin-konjugate, deren verfahren zur herstellung und verwendung für die heilung von thrombosen
DE59404911D1 (de) Verfahren zur Herstellung von Stiften, insbes. von Kosmetikstiften
DE69620755D1 (de) Myrteextrakt enthaltendes haarpflegemittel, verfahren zur herstellung und verwendung insbesondere für eine antischuppenbehandlung
ATE336992T1 (de) Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz- erkrankungen
ATE185137T1 (de) Verfahren zur industriellen herstellung von 4- chloro-3-sulfamoyl-n-(2,3-dihydro-2-methyl-1h- indol-1-yl)-benzamid
DE69205535D1 (de) Verfahren zur Herstellung von Phenylbutyronitrilen und Verwendung in der Parfümerie des 2,2-Dimethyl-4-Phenyl-Valeriannitrile.
ATE411390T1 (de) Synthetische säugetier alpha-n- acetylglukosaminidase und dafür kodierende genetische sequenzen
DE19681159D2 (de) Multimere Formen von IL-16, Verfahren zu ihrer Herstellung und Verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee